Pharmaceuticals
Biosyngen's First-in-class Cell Therapy BRG01 Receives FDA Fast Track Designation
SINGAPORE, July 12, 2023 /PRNewswire/ -- On July 6, 2023, Biosyngen received an official notification from the U.S. Food and Drug Administration (FDA) granting Fast Track Designation (FTD) to its revolutionary first-in-class immunotherapy, BRG01, for the treatment of relapsed/metastatic nasophary...
2023-07-12 13:38
4455
Creating the China-Singapore Translational Medicine Center - Biosyngen's pursuit to be a leading player in the CGT industry globally hits new milestone.
SINGAPORE, July 12, 2023 /PRNewswire/ -- This is a model of cooperation between Singapore and China, more importantly, working jointly in the area of research and development. Through this initiative, China Singapore Knowledge City paths the way to attract both local and overseas therapeutic asse...
2023-07-12 10:32
3893
Sciwind Biosciences Announces Publication of Discovery, Preclinical, and Phase 1 Clinical Trial Results of Ecnoglutide (XW003) in Molecular Metabolism
HANGZHOU, China and SAN FRANCISCO, July 12, 2023 /PRNewswire/ -- Sciwind Biosciences Co., Ltd., a clinical-stage biopharmaceutical company focusing on discovering and developing innovative therapies to treat metabolic disease, today announced the publication of discovery, preclinical characteriza...
2023-07-12 10:00
4052
GI Dynamics Announces Company Rebrand as Morphic Medical® Reintroducing Flagship Product as RESET®
BOSTON, July 11, 2023 /PRNewswire/ -- GI Dynamics, creator of the world's first medical device designed to target the underlying cause of type 2 diabetes, is proud to announce its rebrand to Morphic Medical and the introduction of RESET, formally known as EndoBarrier®. This transformative shift r...
2023-07-12 07:12
2788
Race executes global license agreement with City of Hope to access FTO IP
* Race executes worldwide license agreement with City of Hope, one of the largest cancer research and treatment organisations inthe United States. * Under the agreement, Race will exclusively secure rights to a City of Hope patent application and associated know-how identifying that bisantrene...
2023-07-11 07:30
3952
Rx-360 Expands Trademark Portfolio to Japan
PHILADELPHIA, July 10, 2023 /PRNewswire/ -- Rx-360 is pleased to announce that the consortium has now expanded their trademark registration for Joint Audit Program® logo to now include Japan. Through the achievement of this milestone, Rx-360 has secured trademark registration for Rx360 and the J...
2023-07-10 18:00
2607
Calling Bright Minds in Southeast Asia, Bio Farma and MIT Hacking Medicine is Set to Revolutionize Healthcare with a 4-Day Hackathon
JAKARTA, Indonesia, July 10, 2023 /PRNewswire/ -- Bio Farma
2023-07-10 15:19
3851
RemeGen and Innovent Collaborate on Clinical Trials to Evaluate the Potential of RC88 and RC108 Combined with PD-1 Therapy for Advanced Solid Tumors
The partnership focuses on combining novel antibody-drug conjugates RC88 and
RC108 with a PD-1 inhibitor sintilimab for enhanced treatment outcomes
YANTAI, China, July 10, 2023 /PRNewswire/ -- RemeGen Co., Ltd.
2023-07-10 10:24
3294
Kexing Biopharm Makes it into China's Top 20 Biopharmaceutical Enterprises (Blood Products, Vaccines and Insulin) for Two Consecutive Years
SHENZHEN, China, July 7, 2023 /PRNewswire/ -- Kexing Biopharmaceutical (688136.SH) has accomplished the impressive feat of being recognized onJune 27 as one of "China's Top 20 Biopharmaceutical Enterprises" (blood products, vaccines and insulin) for two consecutive years. This prestigious sub-lis...
2023-07-07 19:43
6171
Transcenta Received Approvals from China CDE and South Korea MFDS to Initiate TranStar 301 Global Phase III Pivotal Trial of Osemitamab (TST001)
SUZHOU, China, July 7, 2023 /PRNewswire/ -- Transcenta Holding Limited ("Transcenta") (HKEX: 06628), a clinical stage biopharmaceutical company with fully-integrated capabilities in discovery, research, development and manufacturing of antibody-based therapeutics, announces that it has received ...
2023-07-07 15:52
4308
CARING PHARMACY CELEBRATES UNIFIED CARING MEMBERSHIP PROGRAMME WITH GEORGETOWN PHARMACY AND WELLINGS PHARMACY
KUALA LUMPUR, Malaysia, July 6, 2023 /PRNewswire/ -- CARiNG Pharmacy, Georgetown Pharmacy, and Wellings Pharmacy, all subsidiaries under CARiNG Pharmacy Group, are proud to announce their newly revamped Caring Membership Mobile App which unifies all 3 pharmacies' membership programme into one. To...
2023-07-06 18:00
4524
MGI's DNBSEQ-T7* Receives Approval for Clinical Use in South Korea
SEOUL, South Korea, July 6, 2023 /PRNewswire/ -- MGI Tech Co. Ltd. (MGI), a company committed to building core tools and technology to lead life science, announced its ultra-high-throughput genetic sequencer DNBSEQ-T7 received the medical device registration certificate from the Korea Ministry of...
2023-07-06 09:00
4092
Brii Biosciences Broadens its Leadership in Hepatitis B with a Portfolio Now Addressing Disease's Burdens from Prevention to Cure
Extension of BRII-179 license from VBI Vaccines to global rights bolsters Brii Bio's position to achieve best-in-class HBV functional cure in broad patient populations Company also acquires exclusive rights to PreHevbri®, a clinically differentiated, 3-antigen prophylactic vaccine, from VBI inGr...
2023-07-06 07:25
4930
Brii Biosciences Provides Latest Clinical Development and Corporate Updates
Company extends BRII-179 license to global rights and introduces preventive vaccine, PreHevbri® in Greater China and Asia Pacific markets New data from BRII-835 + PEG-IFN-α study have demonstrated that robust anti-HBs antibody responses at the end of treatment are associated with sustained HBsA...
2023-07-06 07:19
5466
AFTER FIVE YEARS OF SUCCESSFUL EXPERIENCE INTERNATIONALLY, BIOCON BIOLOGICS' HULIO® BIOSIMILAR TO HUMIRA®, NOW AVAILABLE IN THE UNITED STATES
BRIDGEWATER, N.J. and BENGALURU, India, July 3, 2023 /PRNewswire/ -- Biocon Biologics Ltd (BBL), a subsidiary of Biocon Ltd, today announced that HULIO® (adalimumab-fkjp) injection, a biosimilar to Humira® (adalimumab), is now available to patients inthe United States after five years of experien...
2023-07-04 01:22
3054
Henlius Forecasts Profit in 1H 2023
Spurring a Seamless R&D, Manufacturing, and Commercialisation Positive Cycle SHANGHAI, July 3, 2023 /PRNewswire/ -- Henlius (2696.HK) released a positive profit forecast. Based on the preliminary assessment of the unaudited comprehensive management accounts for the six months endedJune 30, 2023, ...
2023-07-03 18:59
5905
SHL Medical acquires 100% of the shares in Swiss company LCA Automation
SHL Medical announces the acquisition of LCA Automation AG, a Swiss innovative automation solutions provider. The acquisition is SHL Medical's response to the growing market demand for drug delivery solutions and will support its manufacturing operations globally, especially the upcomingSwiss man...
2023-07-03 17:00
4344
Innovent and IASO Bio Announce the NMPA Approval of FUCASO®, the First Fully-human BCMA CAR-T Therapy, for the Treatment of Relapsed or Refractory Multiple Myeloma
ROCKVILLE, Md. and SUZHOU, China, July 3, 2023 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, autoimmune, metabolic, ophthalmology and...
2023-07-03 08:00
6291
Lifera and CENTOGENE, Enter Strategic Collaboration - Forming Saudi Arabian Joint Venture to Increase Access to Leading Data-Driven Multiomic Testing
* Joint Venture (JV) combines CENTOGENE's global leadership in multiomics with local insight of Lifera, a biopharmaceutical company wholly owned by the Public Investment Fund (PIF) based inRiyadh. * JV focuses on providing state-of-the-art multiomic testing services to patients, health system...
2023-07-02 14:00
4628
Transcenta Presented PFS Data by CLDN18.2 Expression Level from Phase I/II Study of Osemitamab (TST001) plus CAPOX as the First-Line Treatment of Advanced G/GEJ Cancer at ESMO GI Annual Congress 2023
* 64 patients with CLDN18.2 positive G/GEJ cancer were enrolled in TranStar102 (TST001-1002). CLDN18.2 positivity is defined as ≥10% tumor cells with ≥1+ intensity. These patients represent approximately 55% of all G/GEJ adenocarcinomas. The overall median PFS was 9.5 months with no differences...
2023-06-30 17:33
3944
Week's Top Stories
Most Reposted
Agoda Begins Limited Public Beta of New AI Assistant That Turns Travel Ideas into Bookable Trips
[Picked up by 289 media titles]
2026-09-15 11:00
Avnet and The University of Hong Kong Open EMUS Lab to Accelerate AI Innovation and Commercialization in Hong Kong
[Picked up by 281 media titles]
2026-09-17 13:09
Sovereign Investment Institutions Launch China-ASEAN Joint Investment Council
[Picked up by 267 media titles]
2026-09-16 09:09
USSEC Advances Aquaculture Feed Formulation in Asia
[Picked up by 264 media titles]
2026-09-17 09:00
CLP Power Hosts AESIEAP CEO Conference 2026 in Hong Kong
[Picked up by 260 media titles]
2026-09-15 19:07
Most Read
ALLSWIFIT Introduces ActiveRise+, a Stable Carbon-Plate Running Shoe Built to Help Everyday Runners Train Smarter and Run Stronger
2026-09-11 21:00
14673
Cheetah Mobile Announces Second Quarter 2026 Unaudited Consolidated Financial Results
2026-09-11 10:36
10841
